ReviewCancers2024
Wire-Free Targeted Axillary Dissection: A Pooled Analysis of 1300+ Cases Post-Neoadjuvant Systemic Therapy in Node-Positive Early Breast Cancer.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- Targeted Axillary Dissection Versus Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy: Why Staging Accuracy Matters.Annals of surgical oncology · 2026Article
- Axillary surgery after neoadjuvant therapy: rethinking completion axillary dissection for residual micrometastatic disease.Translational cancer research · 2026Article
- Titanium clip for lymph node marking in node-positive breast cancer: a reliable, cost-effective approach to targeted axillary dissection following neoadjuvant chemotherapy.Ecancermedicalscience · 2026Article
- Targeted axillary dissection versus sentinel lymph node biopsy after neoadjuvant chemotherapy: are we underestimating the clinical significance of staging accuracy?Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Translating NSABP B-51 findings into practice: rethinking regional nodal irradiation in breast cancer.Translational cancer research · 2025Article
- Targeted axillary dissection in breast cancer patients with metastatic nodal disease: a prospective study on localization techniques and oncological outcomes.Gland surgery · 2025Article
- Reevaluating regional nodal irradiation after nodal pathologic complete response to neoadjuvant chemotherapy: toward individualized de-escalation.Gland surgery · 2025Article
- Article
- Critical appraisal of a data mining model for predicting nodal response to neoadjuvant treatment in breast cancer.Breast cancer research and treatment · 2025Article
- Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.Breast cancer research and treatment · 2025Article
- Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination.Hepatology international · 2025Article
- Axillary management in patients with sentinel lymph node micrometastases following neoadjuvant systemic therapy: a call for de-escalation.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in neoadjuvant systemic therapy (NST) have significantly improved pathologic complete response rates in early breast cancer, challenging the role of axillary lymph node dissection in nose-positive patients. Targeted axillary dissection (TAD) integrates marked lymph node biopsy (MLNB) and tracer-guided sentinel lymph node biopsy (SLNB). The introduction of new wire-free localisation markers (LMs) has streamlined TAD and increased its adoption. The primary endpoints include the successful localisation and retrieval rates of LMs. The secondary endpoints include the pathological complete response (pCR), SLNB, and MLNB concordance, as well as false-negative rates. Seventeen studies encompassing 1358 TAD procedures in 1355 met the inclusion criteria. The localisation and retrieval rate of LMs were 97% and 99%. A concordance rate of 67% (95% CI: 64-70) between SLNB and MLNB was demonstrated. Notably, 49 days (range: 0-272) was the average LM deployment time to surgery. pCR was observed in 46% (95% CI: 43-49) of cases, with no significant procedure-related complications. Omitting MLNB or SLNB would have under-staged the axilla in 15.2% or 5.4% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.